F2RL1 and hypertriglyceridemia: A cell-penetrating, lipidated PAR2 inhibitor, PZ-235 reduces fatty liver steatosis and hypertriglyceridemia by up to 50% (16), suggesting an inverse relationship between PAR2 and hypertriglyceridemia.